

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

: Thierry BOON-FALLEUR et al.

Serial No.

08/819,669

Filed

: March 17, 1997

For

TUMOR, REJECTION, ANTIGEN PRECURSORS, TUMOR

REJECTION ANTIGENS AND USES THEREOF

Art Unit

1644

Examiner

T. Cunningham

Hon. Commissioner of Patents

September 23, 1999

and Trademarks

BOX AF

Washington, D.C. 20231

LETTER

SIR:

In response to the Notice of August 31, transmitted herewith is a new CRF and paper copy of sequence information presented therein. It is asked that these materials be used to REPLACE the current CRF and paper copy of same.

LUD 5253.5 DIV-JEL/NDH (09885911)

It is noted that the action of May 7, 1999 did <u>NOT</u> include the points raised herein, although it was a sequence compliance letter. It is believed that the examiner is unduly prolonging

prosecution.

The undersigned hereby asserts that to the best of his knowledge, the attached CRF and accompanying paper copy of same present information that is identical to each other and to information in the application as filed. No new matter is believed presented.

Respectfully submitted,

FULBRIGHT & JAWORSKI, L. L.P.

Bv:

Norman D. Hanson

Reg. No. 30,946

666 Fifth Avenue

New York, New York 10103

Direct Line: 212-318-3168

General Number: 212-318-3000

Application No. 03/819,669

NOTICE TO COMPLE WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application doe not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

200000000000000000000000000000000000000
1. This application clearly fails to comply with the requirements of 37 CFR 1.
- 1.825. Applicant's attention is directed to these regulations, published at 1114 OG May 15, 1990 and at 55 FR 18230, May 1, 1990. SEE ATTACHER SHEET
2. This application does not contain, as a separate part of the disclosure on
paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been
submitted as required by 37 CFR 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted
However, the content of the computer readable form does not comply with the requiremen of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been
found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer
readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
□ 7.
Other:
Applicant must provide:
Applicant must provide:
An initial or substitute computer readable form (CRF) copy of the "Sequence
Listing"
An initial or substitute paper copy of the "Sequence Listing", as well as an
amendment directing its entry into the specification
oxdot A statement that the content of the paper and computer readable copies are the s

1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please conta

and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400